Production (Stage)
Verve Therapeutics, Inc.
VERV
$4.36
-$0.02-0.46%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 32.98M | 13.08M | 6.87M | 6.69M | 5.70M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 32.98M | 13.08M | 6.87M | 6.69M | 5.70M |
| Cost of Revenue | 54.46M | 55.05M | 49.94M | 50.98M | 48.38M |
| Gross Profit | -21.48M | -41.97M | -43.07M | -44.29M | -42.68M |
| SG&A Expenses | 15.15M | 14.10M | 13.84M | 14.55M | 14.16M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 69.61M | 69.15M | 63.78M | 65.53M | 62.54M |
| Operating Income | -36.64M | -56.07M | -56.91M | -58.84M | -56.84M |
| Income Before Tax | -30.95M | -49.96M | -50.03M | -49.74M | -48.63M |
| Income Tax Expenses | 79.00K | 73.00K | 104.00K | 66.00K | 106.00K |
| Earnings from Continuing Operations | -31.03M | -50.04M | -50.13M | -49.81M | -48.74M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -31.03M | -50.04M | -50.13M | -49.81M | -48.74M |
| EBIT | -36.64M | -56.07M | -56.91M | -58.84M | -56.84M |
| EBITDA | -34.92M | -54.37M | -55.16M | -57.17M | -55.21M |
| EPS Basic | -0.35 | -0.58 | -0.59 | -0.59 | -0.59 |
| Normalized Basic EPS | -0.22 | -0.36 | -0.37 | -0.37 | -0.37 |
| EPS Diluted | -0.35 | -0.58 | -0.59 | -0.59 | -0.59 |
| Normalized Diluted EPS | -0.22 | -0.36 | -0.37 | -0.37 | -0.37 |
| Average Basic Shares Outstanding | 88.80M | 86.87M | 84.63M | 84.23M | 83.13M |
| Average Diluted Shares Outstanding | 88.80M | 86.87M | 84.63M | 84.23M | 83.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |